Literature DB >> 11816821

Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin.

G M Verleden1, R M du Bois, D Bouros, M Drent, A Millar, J Müller-Quernheim, G Semenzato, S Johnson, G Sourvino, D Olivier, A Pietinalho, A Xaubet.   

Abstract

Understanding of the cellular and cytokine interactions associated with inflammation and fibrosis in interstitial lung diseases (ILDs) has increased substantially during the past few years. Presently, many agents are known to have the ability to induce ILDs, although only a small percentage of exposed individuals will develop the disease. In addition, the majority of ILDs are of unknown origin and many are labelled "idiopathic". Therefore, host susceptibility, genetic factors and, possibly, environmental cofactors may be important for the clinical expression of ILDs. The present review reports evidence of the genetic predisposition to develop ILDs of unknown origin, more specifically sarcoidosis, idiopathic pulmonary fibrosis (IPF), lymphangioleio-myomatosis and ILDs, in systemic sclerosis. For instance, for sarcoidosis and IPF several histocompatibility antigens have been associated with the development and/or the clinical presentation of the disease. Furthermore, there are also several types of ILD that are associated with inherited disorders, of which the tuberous sclerosis complex is only one example. This clearly indicates that pulmonary fibrosis can be influenced by genetic factors. Familial occurrence of sarcoidosis and IPF is also well known, although the exact modes of inheritance are debatable. Several studies have shown that extrinsic factors, such as single or multiple fibrosing agents, probably contribute to the development of clinical ILDs of unknown origin. It is probable that some of these studies deal with patients who do not have classical IPF, as recently defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) consensus. Therefore, the true role of these extrinsic factors in the development of IPF, or even sarcoidosis, remains speculative. With the help of animal studies and, more specifically, by using knock-out mice, it may be possible in the near future to unravel at least some of the genes that are responsible for the increased susceptibility of the development of interstitial lung diseases.

Entities:  

Mesh:

Year:  2001        PMID: 11816821

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN: 0904-1850


  8 in total

1.  Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.

Authors:  Akihiko Gotoh; Kazuma Ohyashiki; Kazuo Oshimi; Noriko Usui; Tomomitsu Hotta; Kazuo Dan; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

2.  Familial interstitial lung disease in two young Korean sisters.

Authors:  Hyo-Bin Kim; So-Yeon Lee; Ja-Hyung Kim; Ju-Young Jang; Jooryung Huh; Seong-Jong Park; Soo-Jong Hong
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

3.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

Review 4.  Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment.

Authors:  Nasreen Khalil; Robert O'Connor
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

Review 5.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

6.  Association between variations in cell cycle genes and idiopathic pulmonary fibrosis.

Authors:  Nicoline M Korthagen; Coline H M van Moorsel; Nicole P Barlo; Karin M Kazemier; Henk J T Ruven; Jan C Grutters
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

7.  Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015.

Authors:  Fernando Pedraza-Serrano; Rodrigo Jiménez-García; Ana López-de-Andrés; Valentin Hernández-Barrera; Gema Sánchez-Muñoz; Luis Puente-Maestu; Javier de-Miguel-Díez
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 8.  Interstitial Lung Diseases in Developing Countries.

Authors:  Pilar Rivera-Ortega; Maria Molina-Molina
Journal:  Ann Glob Health       Date:  2019-01-22       Impact factor: 2.462

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.